Management of Breast Cancer in Patients with Systemic Lupus Erythematosus

Initial Oncologic Assessment

The European Society for Medical Oncology (ESMO) guidelines should be followed for breast cancer workup, regardless of SLE status, including performing biopsy of the breast lesion to confirm histology and assess ER, PgR, and HER2 status to guide treatment decisions, as tumor biology determines therapeutic approach 1, 2
Complete staging with CT chest/abdomen and bone imaging (CT plus bone scan or PET-CT) should be done to determine disease extent 2
Additional biomarkers should be assessed based on tumor subtype, including germline BRCA1/2 in HER2-negative disease, PD-L1 in triple-negative breast cancer, and PIK3CA in ER/PgR-positive HER2-negative disease 1, 2

Before initiating chemotherapy or immunosuppressive cancer therapy, infectious disease screening should be completed and lupus control optimized, including screening for tuberculosis, HIV, hepatitis B, and hepatitis C 3
CMV antigenaemia should be tested if high-dose corticosteroids are planned, as CMV infection can mimic active lupus and occurs in 18-44% of patients on pulse steroids 3
Complement levels (C3, C4) should be measured alongside anti-dsDNA to assess current lupus activity, as low complement with elevated anti-dsDNA indicates active disease 4, 5
Baseline CBC, comprehensive metabolic panel, urinalysis with protein-to-creatinine ratio, and serum creatinine should be obtained to evaluate for lupus organ involvement, particularly renal disease 6, 5

For localized breast cancer, surgery, radiation, and systemic therapy should be proceeded with as indicated by tumor biology, with modifications including coordinating timing of cancer treatment with rheumatology to ensure lupus is not in active flare before initiating chemotherapy 3
Hydroxychloroquine should be continued throughout cancer treatment unless contraindicated, as it reduces lupus flare risk and does not interfere with chemotherapy 6
High-dose glucocorticoids should be minimized or avoided until infectious screening is complete 3, 6
Lupus flares should be monitored every 3-6 months during active cancer treatment, as chemotherapy-induced immunosuppression may paradoxically trigger autoimmune activity 6

A structured monitoring protocol should be established addressing both diseases, including monitoring anti-dsDNA quantitatively and complement levels every 3-6 months using the same laboratory method consistently 4, 5
Lupus nephritis should be assessed with urinalysis and urine protein-to-creatinine ratio before each chemotherapy cycle, as both lupus and certain chemotherapies can cause renal toxicity 6, 5
Severe cytopenias should be screened more frequently than standard oncology protocols, as both lupus and chemotherapy cause bone marrow suppression 3, 6
Infections should be monitored aggressively given dual immunosuppression from lupus and cancer therapy 3

Inactivated vaccines should be administered before initiating cancer treatment when possible, including influenza and pneumococcal vaccines following guidelines for immunosuppressed patients, preferably when lupus disease is inactive 6
Live vaccines should be avoided during chemotherapy and immunosuppressive therapy 6

Formal coordination should be established between oncology and rheumatology with defined roles, including oncology leading cancer treatment decisions based on tumor biology and stage 1, 2
Rheumatology should manage lupus activity, adjust immunosuppression, and monitor for autoimmune complications of cancer therapy 6
Both teams should communicate regarding timing of treatments and shared toxicities (cytopenias, renal dysfunction, infections) 3, 6

For patients achieving cancer remission, increased comorbidity risks from both diseases should be addressed, including screening for cardiovascular disease more aggressively, as both SLE and certain cancer therapies increase cardiovascular risk 3
Bone health should be monitored with DEXA scanning, as both lupus and cancer treatments increase osteoporosis risk 3
Cancer screening should be continued per general population guidelines, though recognizing that ongoing SLE may confer some protection against future breast cancer 3

Syphilis may generate cross‑reactive antibodies that interfere with serologic assays, and specific anti‑dsDNA positivity has been reported, although it is less well documented. 7
Acute Epstein‑Barr virus infection (infectious mononucleosis) can produce antibodies that cross‑react in anti‑dsDNA assays; these antibodies are typically transient and disappear after viral clearance. 7
Cytomegalovirus infection can yield positive anti‑dsDNA results, especially in immunocompromised patients. 7

Hepatitis A, B, and C infections have been shown to cause positive anti‑dsDNA antibodies, particularly when patients exhibit systemic clinical manifestations. 8
Screening for hepatitis B and C infection is recommended before starting immunosuppressive therapy to avoid misinterpretation of anti‑dsDNA positivity. 9

HIV infection has been associated with the presence of positive anti‑dsDNA antibodies. 10

Parvovirus B19 infection can lead to transient anti‑dsDNA positivity that resolves after the acute illness. 8

Toxoplasmosis has been documented to cause positive anti‑dsDNA antibodies, most often during active systemic infection. 8

When anti‑dsDNA is detected, a targeted infection screen should be performed—including tests for tuberculosis, HIV, hepatitis B and C, Epstein‑Barr virus, cytomegalovirus, and relevant parasitic infections based on exposure history—to differentiate infection‑related false‑positives from true systemic lupus erythematosus. 8, 9